TD Cowen Maintains Hold Rating on Merck After Enflonsia Vaccine Update

Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its Hold rating and $100 price target on Merck & Co., Inc. (NYSE:MRK) after a vote from the Advisory Committee on Immunization Practices (ACIP) the company’s Enflonsia vaccine.

TD Cowen Maintains Hold Rating on Merck After Enflonsia Vaccine Update

Pixabay/Public Domain

Enflonsia is a component of Merck & Co., Inc. (NYSE:MRK)’s expanding vaccine portfolio, which, together with its oncology and other pharmaceutical operations, has grown in importance as a revenue source.

Merck & Co., Inc. (NYSE:MRK)’s vaccine business could be boosted by the ACIP vote, which could open up new markets for the pharmaceutical giant. The committee’s choice might “unlock significant potential” for the product, according to TD Cowen analyst commentary.

Merck & Co., Inc. (NYSE:MRK) is a well-known American multinational pharmaceutical firm. Internationally recognized as Merck Sharp & Dohme (MSD), the company is a global provider of prescription medications, vaccines, biologic therapies, and animal health products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.